S. Dixon

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

V. Gordeuk, Winfred C. Wang, Y. Yaron, 2017 .

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

K. Dufu, J. Howard, P. Telfer, 2019, Blood.

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment

R. Preston, T. Marbury, Michelle L. Green, 2020, Journal of clinical pharmacology.

Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years

A. Inati, R. Kalpatthi, N. Griffin, 2022, Pediatric blood & cancer.

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Clark Brown, D. Archer, J. Lehrer-Graiwer, 2019, Blood.